<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=182969788831632&amp;ev=PageView&amp;noscript=1">

3 min read

Pathology News Roundup: March 22, 2022

Featured Image

USCAP Annual Meeting: The 111th annual meeting of the United States & Canadian Academy of Pathology (USCAP) is currently underway in Los Angeles, Calif. The meeting convened on March 19 and continues through March 24.

This year the USCAP is offering three ways to participate: in-person, online, or via a hybrid experience. The online experience offers a variety of sessions live streamed from Los Angeles. These sessions will cover the breadth and depth of pathology. All sessions that are offered in the online experience will be recorded for later access.

The meeting opened on Saturday, March 19 with the Maude Abbott Legacy award and lecture by Dr. Cristina Antonescu, providing an overview of the recent molecular advances that have had a significant impact on the classification, diagnosis and management of soft tissue tumors. Dr. Antonescu is the Director of Bone and Soft Tissue Pathology at Memorial Sloan Kettering Cancer Center in NY. The weekend events also featured the USCAP Honors celebration, followed Companion Society meetings and professional development Workshops.

Other annual meeting favorites, including poster and platform sessions, short and special courses, interactive microscopy, Long Course, and the Exhibit Hall, started on Monday, March 21.

Participants are eligible for Continuing Medical Education (CME) credits. The deadline to claim CME is Friday, September 30, 2022.

Follow along with the events at the USCAP meeting by checking out the #USCAP2022 hashtag on Twitter.

VB Divider

First FDA Clearance for Scanner Agnostic Digital Pathology Software. Digital pathology and cancer informatics provider Inspirata announced that it has received U.S. Food and Drug Administration (FDA) clearance for its Dynamyx digital pathology software. This clearance enables Dynamyx customers to use whole slide images (WSIs) for primary diagnosis in place of traditional glass slides, yielding an array of powerful benefits to pathologists and laboratories.

Dynamyx holds the first FDA clearance for digital pathology software with multiple scanners. Inspirata says this highlights the company's core commitment to a scanner agnostic and open platform that will allow its customers to select the best scanners for their laboratory.

Screen-Shot-2020-12-04-at-12.27.13-AM-1024x541
Image via Inspirata.


“FDA clearance for Inspirata’s Dynamyx software is exciting, as this will pave the way for more clinical adoption of digital pathology and AI tools for clinical applications, as well as teaching, education, and research,” said Dr. Anil Parwani, Vice-Chair of Anatomic Pathology at the Ohio State University’s Wexner Medical Center. “As a current user of Dynamyx, I am looking forward to using the intuitive user interface with the many annotation tools, universal viewer, and customizable third-party AI applications that can be made available as needed by the pathologists.”

In response to the COVID-19 pandemic in early 2020, the FDA and CMS announced temporary waivers of 510(k) requirements and CLIA licensing requirements, allowing Dynamyx to be used for primary diagnosis without the need of a 510(k). Despite this waiver, Inspirata pursued FDA clearance.

“Inspirata recognizes our customer’s desire to have the assurance of an FDA market clearance. We are confident that this significant milestone will help our customers communicate the maturity of digital pathology across their organization,” said Mark Lloyd, Executive Vice President and Founder of Inspirata. “We are immensely proud of our hard work leading up to this achievement and believe that FDA clearance is critical for all vendors for the long-term success of the industry.”

VB Divider

CAP Annual Report. The College of American Pathologists (CAP) released its 2021 Annual Report

The report outlines the financial health of the organization, as well as detailing advocacy wins, laboratory quality measures, and efforts to support the CAP membership.

CAP President Emily Volk, MD, FCAP, and CEO Stephen Myers state in the report's introduction, "The challenges we faced in 2021 required a strong, engaged membership, and we’re proud of how we’ve grown. One exciting development was the launch of the new MyCAP app, which improves member access to content and resources such as the Cancer Protocols and advocacy alerts when we need to mobilize to protect our patients and the profession. We continue our work to grow the pathology pipeline to sustain the future of our specialty. Recognizing the value of a diverse pipeline, we formed the first-ever Diversity, Equity, Inclusion Committee to support the visibility and participation of underrepresented pathologists."

Financially-speaking, the CAP's total 2021 operating revenues were $251.7 million, $3.1 million (1.2%) better than the Board-approved target and $14.3 million (6.0%) above fiscal year 2020 levels, as the CAP says nearly all revenue streams recovered faster than anticipated from the pandemic’s economic effect.

VB Divider

Voicebrook's Pathology News Roundup features industry headlines and insights that pathology professionals are talking about. Think we should be covering something in particular? 

Send your suggestions to content@voicebrook.com